Skip to main content
OpenTrials
Completed

NCT Number: NCT00954096

Nicotine Patch, Blood Flow and Oxidative Stress Study

This study will address the hypothesis that nicotine, like cigarette smoking acting as a pro-oxidant may have adverse effects on arterial function.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

About this study

Smoking causes >400,000 deaths from cardiovascular disease (CVD) per year. The molecular basis of smoking induced tissue injury remains unclear but considerable evidence supports a role for oxidant stress (OS).

Arterial function has been shown to be impaired in smokers even before the onset of angiographically demonstrable atherosclerosis. Defects in endothelium dependant flow mediated vasodilatation (FMD) are seen in those at risk of or with overt vascular disease.

Cigarette smoking is highly addictive. Spontaneous quit rates approximate 3%. Even those using nicotine replacement therapy (NRT) have high relapse rates (67-75%) on completion of the 8-12 week course of NRT. Thus there is interest in the use of extended NRT as a "safer" alternative to cigarette smoking. However such assumptions may be premature. Nicotine demonstrates proxidant effects in vitro and in small studies has been associated with endothelial dysfunction. Studies simultaneously assessing the effects of nicotine on oxidative stress and arterial function in humans have not been performed.

The current proposal will address the hypothesis that nicotine, like cigarette smoking acting as a pro-oxidant may have adverse effects on arterial function.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy individuals
  • Nonsmokers who have never smoked
  • Normal medical history
  • Normal physical examination
  • Normal laboratory data
  • Negative urinary pregnancy test for females

Exclusion criteria

  • Previous CVD
  • Chronic medication use
  • History alcoholism
  • History of smoking
  • Current pregnancy
  • Subjects, who have less than or equal to 60% platelet aggregation in response to arachidonic acid will also be excluded.

Treatment and study plan

transdermal nicotine patch (7mg)

Drug

A 7mg transdermal nicotine patch will be applied to the subject's arm for an 8 hour period.

Other names: Nicotine patch, Habitrol, Nicoderm CQ, Nicotrol

Primary outcomes

  1. Assess the dose-related effects of nicotine in humans, on novel indices of lipid peroxidation, protein oxidation and DNA modification by lipid adducts.

    Time frame: 1 - 3 years

Secondary outcomes

  1. Assess the dose-related effects of nicotine in humans on COX activation.

    Time frame: 1 year

  2. Assess the dose-related effects of nicotine in humans on blood flow mediated arterial function.

    Time frame: 3 - 6 months

Sponsors and collaborators

Lead sponsor

University of Pennsylvania

Other

Collaborators

  • National Institutes of Health (NIH)

Registry information

Official study title

The Effect Of Nicotine On Indices Of Arterial Function And Oxidative Stress

Important dates

Study start
2002
Primary completion
2006
Study completion
2006
First posted
Aug 6, 2009
Registry last updated
Oct 27, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.